<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941343</url>
  </required_header>
  <id_info>
    <org_study_id>ALFUS_L_01816</org_study_id>
    <nct_id>NCT00941343</nct_id>
  </id_info>
  <brief_title>Benign Prostatic Hyperplasia in Taiwan</brief_title>
  <official_title>Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To assess the sexual function of Benign Prostatic Hyperplasia patients&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To evaluate the association between Lower Urinary Tract Symptoms severity and sexual&#xD;
           disorders&#xD;
&#xD;
        -  To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic&#xD;
           Hyperplasia patients on XATRAL 10mg OD among the different regions&#xD;
&#xD;
        -  To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the&#xD;
           International Index of Erectile Function (IIEF-5)&#xD;
&#xD;
        -  To assess the onset of action of XATRAL 10mg OD&#xD;
&#xD;
        -  To assess the peak urinary flow rate&#xD;
&#xD;
        -  To assess the safety and the tolerability of XATRAL 10mg OD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Male Sexual Health Questionnaire Ejaculation score (MSHQ)</measure>
    <time_frame>At week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSHQ Ejaculation score</measure>
    <time_frame>At week 14, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (I-PSS) including quality of life index</measure>
    <time_frame>At week 1, 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>At week 1, 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>At week 1, 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen</measure>
    <time_frame>At week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Prostatic Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XATRAL 10mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin (XATRAL® - SL770499)</intervention_name>
    <description>One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Male suffering from moderate to severe lower urinary tract symptoms (LUTS), suggestive&#xD;
             of symptomatic Benign Prostatic Hyperplasia (BPH)&#xD;
&#xD;
          -  Sexually active&#xD;
&#xD;
          -  Sexual attempts at least once per month&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Known history of hepatic or severe renal insufficiency&#xD;
&#xD;
          -  unstable angina pectoris&#xD;
&#xD;
          -  concomitant threatening-life condition&#xD;
&#xD;
          -  Previous transurethral resection of the prostate (TURP)&#xD;
&#xD;
          -  Had a minimally invasive procedure within 6 months prior to inclusion&#xD;
&#xD;
          -  Planned prostate surgery or minimally invasive procedure during the whole study period&#xD;
&#xD;
          -  Active urinary tract infection or acute prostatitis&#xD;
&#xD;
          -  Neuropathic bladder&#xD;
&#xD;
          -  Diagnosed prostate cancer&#xD;
&#xD;
          -  Patients having received 5-reductase inhibitors or Lower Urinary Tract Symptoms (LUTS)&#xD;
             related phytotherapy or anti-muscarinics drug for OAB or 1-blockers within 1 month&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Patients receiving any treatment for erectile dysfunction within 1 month prior to&#xD;
             inclusion&#xD;
&#xD;
          -  History of postural hypotension or syncope&#xD;
&#xD;
          -  Known hypersensitivity to alfuzosin&#xD;
&#xD;
          -  Patients illiterate or unable to understand or to complete the questionnaires&#xD;
&#xD;
          -  Patients having participated in any clinical study in the past month&#xD;
&#xD;
          -  Prostate Specific Antigen (PSA)&gt; age specific Prostate Specific Antigen value, without&#xD;
             using prostate biopsy to rule out prostate cancer&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Chang</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

